Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there is no evidence for GM-CSF production by glioblastoma cells in vivo: fresh tumor samples lack the mRNA for GM-CSF and the protein is not detectable in the tumor cyst fluids or the cerebrospinal fluids of glioblastoma patients.
|
1315829 |
1992 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No major gene deletions or rearrangements of G-CSF and GM-CSF genes were demonstrated by Southern blot analysis in the tumors expressing G-CSF and GM-CSF mRNAs except for one of the glioblastomas (G3) in which one chromosome 17 allele was deleted.
|
1701653 |
1990 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We transduced the human glioblastoma cell line D54MG in vitro with genes encoding the proinflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the T cell co-stimulatory molecule B7-2, or both (in a bicistronic vector) via retroviral vectors.
|
9189765 |
1997 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas using autologous tumor cells has many technical pitfalls hindering large scale application and evaluation.
|
16718522 |
2006 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amelioration of cancer stem cells in macrophage colony stimulating factor-expressing U87MG-human glioblastoma upon 5-fluorouracil therapy.
|
24391839 |
2013 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of immune resistance in response to active vaccination in GBM can be reversed with dual administration of CSF-1Ri and PD-1 mAb.
|
28115578 |
2017 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can extend survival and, in a separate study, that dose-intensified temozolomide (DI-TMZ) and adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) potentiate tumor-specific immune responses in patients with glioblastoma.
|
28411277 |
2017 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High levels of G(M)-CSF contribute to the characteristic neutrophilia and lymphopenia of glioblastoma.
|
28459367 |
2017 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biofluid-based detection of GBM focuses on detecting tumor-specific biomarkers in the blood and CSF.
|
29053069 |
2018 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid of 20 non-tumor patients served as controls.Mean levels of L1CAM in tumor cyst fluid were significantly higher in glioblastoma (6118 ± 4095 ng/mL) and metastasis patients (8001 ± 6535 ng/mL) than in CSF of control patients (714 ± 22 ng/mL).
|
30235708 |
2018 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The decision tree analysis of CSF TACI and BAFF levels for patients with a PCNSL diagnosis showed 100% sensitivity and 100% specificity when we attempted to differentiate PCNSL from glioblastoma and CNS inflammatory diseases.
|
30564626 |
2018 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings are relevant to GBM patients because a low level of FGL2 expression with concurrent high GM-CSF expression is associated with higher CD8B expression and longer survival.
|
30683885 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, our results suggested that miR-1246 in the CSF of GBM patients may be a novel biomarker for GBM diagnosis and that treatment targeting microRNA-1246 may contribute to antitumor immunotherapy.
|
31485019 |
2020 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that CMA inhibition in PC promotes GB cell death and the release of high immunogenic levels of granulocyte-macrophage colony stimulating factor (GM-CSF), through deregulation of the expression of cell-to-cell interaction proteins and protein secretion.
|
31548426 |
2019 |